Quick Answer
Praxis Precision Medicines, Inc. reported Stockholders Equity of $878.14 million for the year ending 2025.
- Praxis Precision Medicines, Inc. showed an increase of +97.1% in Stockholders Equity from 2024 to 2025.
- This data is from Praxis Precision Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (23 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$60.46 million | Q3 2019: -$72.06 million | Q1 2024: $229.68 million | Q2 2024: $419.10 million | Q3 2024: $382.67 million | Q1 2025: $439.21 million | Q2 2025: $404.22 million | Q3 2025: $343.51 million.
- Over the full 23 years of available data (2018 to 2025), Praxis Precision Medicines, Inc.'s Stockholders Equity has grown by 2,239.8%.
- Historical annual values: Fiscal year 2025: $878.14 million | Fiscal year 2024: $445.45 million | Fiscal year 2024: $382.67 million | Fiscal year 2024: $419.10 million | Fiscal year 2024: $229.68 million | Fiscal year 2023: $69.67 million | Fiscal year 2023: $86.76 million | Fiscal year 2023: $105.63 million | Fiscal year 2023: $64.47 million | Fiscal year 2022: $76.11 million | Fiscal year 2022: $105.16 million | Fiscal year 2022: $138.87 million | Fiscal year 2022: $191.02 million | Fiscal year 2021: $250.81 million | Fiscal year 2021: $295.92 million | Fiscal year 2021: $333.77 million | Fiscal year 2021: $265.52 million | Fiscal year 2020: $287.46 million | Fiscal year 2020: -$123.26 million | Fiscal year 2020: -$104.08 million | Fiscal year 2020: -$90.76 million | Fiscal year 2019: -$81.01 million | Fiscal year 2018: -$41.04 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: